2021
Management of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis
2020
Preparing for liver surgery with “Alphabet Soup”: PVE, ALPPS, TAE-PVE, LVD and RL
Kim D, Cornman-Homonoff J, Madoff DC. Preparing for liver surgery with “Alphabet Soup”: PVE, ALPPS, TAE-PVE, LVD and RL. HepatoBiliary Surgery And Nutrition 2020, 9: 136-151. PMID: 32355673, PMCID: PMC7188547, DOI: 10.21037/hbsn.2019.09.10.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPre-operative portal vein embolizationRadiation lobectomyVein embolizationPortal vein embolizationPortal vein ligationStandard of careVenous deprivationPostoperative prognosisVein ligationLiver partitionTreatment eligibilityLiver surgeryInadequate augmentationSurgical hepatectomyTumor progressionLiver growthRegenerative techniquesEmbolizationHepatectomyLobectomyALPPSSurgeryPrognosis
2019
Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma
Cornman-Homonoff J, Bassik N, Madoff DC. Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma. Clinical Imaging 2019, 59: 188-191. PMID: 31837541, DOI: 10.1016/j.clinimag.2019.09.012.Peer-Reviewed Case Reports and Technical NotesConceptsRecurrent cholangiocarcinomaOnly potential cureRecurrent intrahepatic cholangiocarcinomaPoor patient outcomesUnresectable diseaseGastrointestinal bleedingChemotherapy administrationMyelosuppressive effectsTherapeutic mainstayDismal prognosisIntrahepatic cholangiocarcinomaVariceal embolizationStent placementPortal veinPatient outcomesPotential cureCholangiocarcinomaEmbolizationCytopeniasBleedingRegimenChemotherapyPatientsSurgeryPrognosisManagement of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng SQ, Teng GJ. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019, 4: 721-730. PMID: 31387735, DOI: 10.1016/s2468-1253(19)30178-5.Peer-Reviewed Original ResearchMeSH KeywordsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticEndovascular ProceduresHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsLiver TransplantationNivolumabPatient Care TeamPhenylurea CompoundsPortal VeinPyridinesQuinolinesRadiotherapy, AdjuvantSorafenibStentsVenous ThrombosisConceptsPortal vein tumor thrombosisTumor thrombosisHepatocellular carcinomaOptimise treatment strategiesTranscatheter arterial therapyAdvanced hepatocellular carcinomaManagement of patientsArterial therapySurgical treatmentTreatment strategiesPhysician preferenceNovel treatmentsCarcinomaThrombosisMultidisciplinary teamPatientsReimbursement schemesTreatmentRevascularisationComorbiditiesManagementPrognosisRadiotherapyActive managementTherapy